21 May 2015
Oxford University researchers have found a promising future treatment for heart disease, by going back to a drug first developed in 1950.
Hydroxychloroquine (HCQ) was created to combat malaria, and was later found to be useful in the treatment of Lupus and rheumatoid arthritis. Now, a team at Oxford University’s Departments of Pharmacology and of Physiology, Anatomy and Genetics has found that the drug can also reduce heart rate. Their report, to be published in journal Heart Rhythm, says that the treatment could benefit people with heart failure.
Dr Rebecca Burton, who led the research, said: “The starting point was a chance observation. A patient being treated for Lupus also had a high heart rate. When the patient started Hydroxychloroquine for the Lupus, their heart rate reduced. We started to think about how the drug might be acting in the heart and began extensive pre-clinical studies in collaboration with [Oxford University heart specialists] Professor Derek Terrar and Professor David Paterson.”
Researchers found that the drug acts on an area of the heart called the sino-atrial node. This group of cells keeps the heart beating by producing a rhythmic electrical signal that is transmitted to the rest of the heart muscle. Within the node HCQ targets a particular protein to restrict an electrical signal known as the ‘funny current’ that is especially important in setting the heart rate.
The effects of HCQ on the heart were studied in the late 1950s but initial findings were not followed up. There were also reports of lowered heart rate as a side-effect in patients treated for other conditions. But the potential of HCQ as a heart treatment had not been pursued fully until the Oxford team began their research.
Dr Burton said: “There is a big drive to find new purposes for existing drugs because it can save years of expensive development and testing. Established drugs have gone through a lot of the regulatory process already. However, the number of drugs on the market and the number of possible conditions are so huge that it takes a fortuitous observation to connect something which might be viewed as an annoying side-effect to something which could have a clinical benefit.”
HCQ has a well-established safety profile. Side-effects are limited and well understood, and it is possible to use it for children and pregnant women under specialist care. The Oxford team’s initial research concentrated on understanding the effects of HCQ and the way in which it worked on the heart as well as safety. HCQ has the potential to be used for heart failure, high blood pressure and angina among other conditions.
The team have patented their results and are now working with the University of Oxford’s company ISIS Innovation to partner with industry in order to complete clinical trials.
Dr Rebecca Capel, the paper’s first author, said: “This treatment has the potential to improve the quality of life for patients who are not responding well to standard heart treatments. There are some very exciting possibilities but we need to go through the full process of clinical trials to really understand its full potential.”
Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation, which funds both Dr Caplan and Dr Burton and which part funded the study, said: “This study is an elegant example of how a chance clinical observation, carefully followed up, can provide evidence in favour of an unexpected new use for an old drug. However, a clinical trial is needed to establish whether HCQ is as safe and effective as existing medicines used to reduce heart rate.”
For more information: Contact the Oxford University News Office on +44 (0)1865 270046 or email email@example.com.
Notes for editors:
The paper, ‘Hydroxychloroquine reduces heart rate by modulating the hyperpolarisation-activated current ‘If’: Novel electrophysical insights and therapeutic potential’, is published in Heart Rhythm (http://www.heartrhythmjournal.com).
The project was supported by the University of Oxford and the Engineering and Physical Sciences Research Council developing Leaders Grant.
Dr Rebecca Burton is funded by the British Heart Foundation. She is the Paul Nurse Fellow in Biomedical Sciences at Linacre College and holds a Winton Churchill Science & Technology fellowship. Most recently she was elected a Fellow of the Royal Society of Arts.
Dr Rebecca Capel is funded by the British Heart Foundation.
Oxford University’s Medical Sciences Division is one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK’s top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
Isis Innovation provides access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.
Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 529 licenses and consulting agreements. Isis Enterprise, our innovation management consultancy, signed 68 deals with university, government and industrial clients from offices around the world.